67 related articles for article (PubMed ID: 10827815)
21. Use of even-numbered carbon atom dicarboxylic salts in parenteral nutrition as fuel substrate.
Mingrone G; Tacchino RM; Castagneto M; Finotti E; Greco AV
JPEN J Parenter Enteral Nutr; 1992; 16(1):32-8. PubMed ID: 1738216
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats.
Bhattaram VA; Paliwal JK; Gupta RC
Biopharm Drug Dispos; 2004 Mar; 25(2):69-75. PubMed ID: 14872554
[TBL] [Abstract][Full Text] [Related]
23. Validation of an HPLC method for the determination of scutellarin in rat plasma and its pharmacokinetics.
Hao X; Cheng G; Sun J; Zou M; Yu J; Zhang S; Cui F
J Pharm Biomed Anal; 2005 Jun; 38(2):360-3. PubMed ID: 15925232
[TBL] [Abstract][Full Text] [Related]
24. Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice.
Abou El Hassan MA; Kedde MA; Zwiers UT; Tourn E; Haenen GR; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Nov; 52(5):371-6. PubMed ID: 12898182
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats.
Tasso L; Neves G; Menegatti R; Fraga CA; Barreiro E; Eifler-Lima V; Rates SM; Costa TD
Eur J Pharm Sci; 2005 Oct; 26(2):194-202. PubMed ID: 16076552
[TBL] [Abstract][Full Text] [Related]
26. Age effect on perfluorooctanoate (PFOA) plasma concentration in post-weaning rats following oral gavage with ammonium perfluorooctanoate (APFO).
Hinderliter PM; Han X; Kennedy GL; Butenhoff JL
Toxicology; 2006 Aug; 225(2-3):195-203. PubMed ID: 16857306
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
28. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats.
Szumiło H
Acta Pol Pharm; 1990; 47(1-2):19-22. PubMed ID: 12959253
[TBL] [Abstract][Full Text] [Related]
30. [Studies on pharmacokinetics of diosmin in rats].
Ma YL; Ma C
Zhongguo Zhong Yao Za Zhi; 2007 Mar; 32(5):418-20. PubMed ID: 17511149
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats.
Sobol E; Yagen B; Winkler I; Britzi M; Gibson D; Bialer M
Drug Metab Dispos; 2005 Oct; 33(10):1538-46. PubMed ID: 16037415
[TBL] [Abstract][Full Text] [Related]
32. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
[TBL] [Abstract][Full Text] [Related]
33. Oral and i.v. pharmacokinetics of isosteviol in rats as assessed by a new sensitive LC-MS/MS method.
Jin H; Gerber JP; Wang J; Ji M; Davey AK
J Pharm Biomed Anal; 2008 Nov; 48(3):986-90. PubMed ID: 18701231
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and metabolism of neferine in rats after a single oral administration.
Huang Y; Bai Y; Zhao L; Hu T; Hu B; Wang J; Xiang J
Biopharm Drug Dispos; 2007 Oct; 28(7):361-72. PubMed ID: 17654697
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of radiolabelled quinlukast in rats.
Syrovatko M; Laznickova A; Laznicek M
J Pharm Biomed Anal; 2005 Jun; 38(2):313-9. PubMed ID: 15925224
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans.
Olsen GW; Chang SC; Noker PE; Gorman GS; Ehresman DJ; Lieder PH; Butenhoff JL
Toxicology; 2009 Feb; 256(1-2):65-74. PubMed ID: 19059455
[TBL] [Abstract][Full Text] [Related]
37. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
[TBL] [Abstract][Full Text] [Related]
39. [Suitability of the peroral administration of the marker creatinine for the quantitative determination of the glomerular filtration rate (GFR) in dogs].
Hartmann H; Baumgardt T; Höchel J
Berl Munch Tierarztl Wochenschr; 2006; 119(1-2):62-7. PubMed ID: 16450711
[TBL] [Abstract][Full Text] [Related]
40. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations.
Ward KW; Azzarano LM; Evans CA; Smith BR
Xenobiotica; 2004 Apr; 34(4):353-66. PubMed ID: 15268980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
